Haupt Pharma, one of the world’s largest
pharmaceutical contract manufacturers and developers, announced today that it has completed the purchase of a Pfizer production site in Latina, Italy. With this asset deal, Haupt Pharma gets access to a plant focused on the
production of antibiotics – especially beta-lactams like penicillin and cephalosporin – and is now able to provide its customers with a variety of special products including hormones, cytotoxics and beta-lactams. In addition, the transaction enables Haupt Pharma to expand its Italian business and improve its market position in the traditional export markets of Italy. At the same time, the company continues to supply Pfizer on a global basis. With the deal, Haupt Pharma’s business volume grows by 30%.
“Through the acquisition of the Latina plant, with its state-of-the-art facilities and highly qualified staff, we are well positioned to significantly expand our international market position,” says Hans-Christian Semmler, chairman of Haupt Pharma. “In Italy, we are expecting a considerable increase in demand for generic medicaments within the next ten years. Moreover, our new beta-lactams competence centre in Latina enables us to complete our product portfolio and to improve our competitive advantages,” he adds.
The Latina plant currently employs more than 450 people, all of whom will be transferred. The site, which produces injectables and solid drugs for human and veterinarian use, is equipped with up-to-date facilities that, together with a world-class quality management system, not only meet but also exceed good manufacturing practice guidelines for the quality control testing of pharmaceutical products.